Low toxicity and favorable clinical and quality of life impact after non-myeloablative autologous hematopoietic stem cell transplant in Crohn’s disease

  • M. A. Ruiz (Creator)
  • Roberto L. Kaiser (Creator)
  • Luiz Gustavo De Quadros (Contributor)
  • Lilian Piron-Ruiz (Creator)
  • Tatiana Peña-Arciniegas (Creator)
  • Mikaell Alexandre Gouvea Faria (Contributor)
  • Rubens Camargo Siqueira (Creator)
  • Flavio Fontes Pirozzi (Creator)
  • Fernanda Soubhia Liedtke Kaiser (Creator)
  • Richard K. Burt (Northwestern University) (Creator)
  • Faria Mikaell (Contributor)



Abstract Objective The incidence of adverse events in myeloablative transplant protocols is high in refractory Crohn’s disease; this study used low doses of cyclophosphamide. Fourteen patients were submitted to non-myeloablative autologous hematopoietic stem cell transplantation. Results The average number of days of anemia (hemoglobin
Date made available2017

Cite this